Aehr Test Systems
AEHR
$82.43
-6.84%
Aehr Test Systems designs, manufactures, and markets advanced test and burn-in equipment for logic, optical, and memory integrated circuits, operating within the semiconductor capital equipment industry. The company has established a distinct identity as a critical, niche supplier of specialized burn-in and test solutions, particularly for the high-reliability demands of the Automotive and Mobility markets. The current investor narrative is overwhelmingly driven by its perceived role in the AI infrastructure build-out, with recent headlines highlighting massive new orders for AI chip testing, a surge in bookings, and a stock price rally fueled by validation of its technology's importance in the semiconductor supply chain.…
AEHR
Aehr Test Systems
$82.43
Related headlines
Investment Opinion: Should I buy AEHR Today?
Rating: Hold. The core thesis is that AEHR represents a high-risk, high-reward speculation on the AI infrastructure build-out, where monumental future potential is fully priced in, leaving asymmetric downside risk if execution falters.
Supporting this view are several data points: the stock trades at an extreme forward EV/Sales of 65.79, implying perfection is already discounted. While the $37.2M bookings backlog is a powerful catalyst, it must be contrasted with three consecutive quarters of revenue decline and a -32.68% net margin. The analyst revenue forecast of $196.1M offers a huge growth target, but achieving it requires flawless execution from a company with just 136 employees. Finally, the technical picture shows a stock that is overextended, trading 94% off its 52-week high after a 1,000%+ rally, with a beta of 2.289 signaling extreme volatility.
The two biggest risks are 1) a delay or failure in converting the $37.2M backlog into high-margin revenue, and 2) a broader de-rating of speculative AI hardware stocks compressing the extreme valuation multiple. This Hold rating would upgrade to a Buy if the company demonstrates sequential revenue acceleration above $15M per quarter and gross margin expansion back above 35%, proving the inflection is real. It would downgrade to a Sell if quarterly revenue fails to materially improve from the $9.88M level in the next report or if cash burn accelerates necessitating significant dilution. The stock is unequivocally overvalued relative to any conventional metric based on current operations, but may be fairly valued or even undervalued if the $196M revenue forecast is achieved ahead of schedule.
Sign up to view all
AEHR 12-Month Price Forecast
The outlook is bifurcated and highly dependent on execution over the next 2-3 quarters. The massive bookings provide a tangible catalyst, but the company must prove it can translate this into sustained, profitable growth—a feat it has not achieved in recent history. The base case of volatile consolidation is most likely, as the market digests the transition from pure narrative to fundamental delivery. The stance would upgrade to bullish on confirmation of revenue acceleration and margin improvement in the next earnings report. It would turn bearish if the next quarter shows no meaningful top-line progress from the $9.88M level, indicating the backlog story may be overstated.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $107.16 and implied upside of +30.0% versus the current price.
Average Target
$107.16
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$66 - $107
Analyst target range
Insufficient analyst coverage is available, with data indicating only one analyst providing estimates. This limited coverage is typical for a small-cap, high-volatility name like Aehr and implies higher uncertainty, less efficient price discovery, and a greater influence of retail and speculative trading on the stock price. The single analyst provides an estimated revenue average of $196.1 million for the upcoming period, which, if achieved, would represent a monumental increase from recent quarterly results and justify the market's excitement. The institutional ratings data shows recent activity, with William Blair upgrading from 'Market Perform' to 'Outperform' on March 2, 2026, a bullish signal that coincided with the stock's major rally. Other firms like Craig-Hallum and Freedom Broker maintain 'Hold' ratings. The wide dispersion in recent analyst actions—from an upgrade to holds—signals high uncertainty and debate about the company's near-term path versus its long-term opportunity, contributing to the stock's elevated volatility.
Bulls vs Bears: AEHR Investment Factors
The investment debate for AEHR is a classic clash between transformative future potential and deteriorating current reality. The bull case, currently possessing stronger short-term momentum, is powered by the massive $37.2M bookings backlog and its association with the secular AI boom, suggesting a fundamental inflection is imminent. The bear case is grounded in severe near-term financial weakness, including declining revenue, negative margins, cash burn, and a valuation that demands perfection. The single most important tension is the timing and magnitude of converting the bookings pipeline into recognized revenue and profit. If AEHR can quickly translate its $37M+ backlog into high-margin sales, the bull thesis will be validated. However, any delay, order cancellation, or failure to achieve the analyst's $196M revenue forecast will likely trigger a violent derating given the extreme valuation and technical positioning.
Bullish
- Massive $37.2M New Bookings: Recent news reports a massive $37.2 million in new bookings, primarily for AI chip testing. This order book, nearly four times the latest quarterly revenue of $9.88M, validates the company's technology and signals a dramatic acceleration in future demand, directly fueling the stock's 145% 1-month surge.
- Extreme Momentum & AI Narrative: The stock has gained 1,003.68% over the past year and 242.05% over the past three months, driven by its perceived critical role in the AI infrastructure build-out. This explosive momentum, with a beta of 2.289, reflects intense market conviction in a transformative growth story, far outpacing the SPY's 30.59% 1-year gain.
- The single analyst covering AEHR projects average revenue of $196.1 million for the upcoming period. Achieving this would represent a monumental ~20x increase from the latest quarterly revenue run-rate, providing a fundamental anchor for the current speculative valuation if execution materializes.
- Healthy Balance Sheet: The company maintains a robust liquidity position with a current ratio of 5.68 and a low debt-to-equity ratio of 0.088. This strong financial footing provides a cushion to fund operations and invest in growth while navigating its current cash burn phase.
Bearish
- Severe Current Financial Deterioration: Recent fundamentals are deeply negative: Q2 revenue declined 26.53% YoY to $9.88M, net margin was -32.68%, and gross margin contracted sharply to 25.75% from 33.90% the prior quarter. The company is unprofitable and burning cash, with TTM free cash flow at -$11.91M.
- Extreme Valuation on Future Hopes: The stock trades at a forward EV-to-Sales of 65.79, an astronomical multiple that prices in flawless execution of the $37M+ backlog and sustained hyper-growth. The trailing PS ratio of 4.79 is deceptively low due to soaring market cap against depressed current sales, indicating valuation is completely unmoored from present operations.
- Cash Burn & Financing Reliance: Operating cash flow was -$1.39M last quarter, and the company raised $9.20M from common stock issuance. With a cash balance of $30.99M, continued cash burn risks future shareholder dilution or the need for debt, threatening equity value if the revenue inflection is delayed.
- Technical Overextension & High Volatility: Trading at 94% of its 52-week high ($102.48) after a 1,000%+ rally, the stock is extremely overextended and vulnerable to a sharp correction. Its beta of 2.289 means it is 129% more volatile than the market, implying severe downside risk if the AI narrative cools or execution stumbles.
AEHR Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +1003.68%. As of the latest close at $95.91, the stock is trading at approximately 94% of its 52-week high of $102.48, positioning it near the absolute peak of its annual range. This proximity to highs reflects extreme momentum but also signals potential overextension and heightened vulnerability to any negative news. Recent short-term momentum is explosive and accelerating, with a 1-month gain of +145.73% and a 3-month gain of +242.05%, far outpacing the broader market's performance (SPY +8.7% and +3.59% over the same periods). This divergence from the longer-term trend is not a reversal but a dramatic acceleration, suggesting a speculative frenzy driven by specific catalysts like major AI-related orders. Key technical support is anchored at the 52-week low of $8.02, though the stock is currently over 1,000% above that level, making it a distant psychological floor. Immediate resistance is the 52-week high of $102.48; a decisive breakout above this level would signal continued momentum, while a failure could trigger a sharp pullback. The stock's beta of 2.289 indicates it is approximately 129% more volatile than the SPY, a critical factor for risk management as it implies outsized moves in both directions.
Beta
2.29
2.29x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$8-$102
Price range past year
Annual Return
+847.5%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | +153.5% | +12.2% |
| 3m | +194.6% | +2.3% |
| 6m | +228.4% | +4.7% |
| 1y | +847.5% | +29.2% |
| ytd | +272.0% | +4.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Revenue growth has been volatile and recently negative; the most recent quarterly revenue (Q2 FY2026) was $9.88 million, representing a significant year-over-year decline of -26.53%. However, this top-line weakness is being overshadowed by a surge in future demand, as indicated by a massive $37.2 million in new bookings reported in recent news. The multi-quarter trend shows revenue peaked at $18.31 million in Q3 FY2025 and has since declined for three consecutive quarters, raising near-term execution concerns. The company is currently unprofitable, with a net income of -$3.23 million and a net margin of -32.68% for the latest quarter. Gross margin contracted sharply to 25.75% from 33.90% in the prior quarter, indicating potential pricing pressure or product mix issues. The trajectory shows profitability deteriorating from a near-breakeven Q3 FY2025 (net margin of -3.51%) to deeper losses, though the market is clearly focused on the future bookings pipeline over current earnings. The balance sheet remains healthy with a strong current ratio of 5.68 and a low debt-to-equity ratio of 0.088. However, cash flow is a major concern: trailing twelve-month free cash flow is negative $11.91 million, and the latest quarter's operating cash flow was -$1.39 million. The company is burning cash to fund operations and growth, relying on its cash balance of $30.99 million and potentially external financing, as evidenced by $9.20 million from common stock issuance in the latest quarter.
Quarterly Revenue
$9884000.0B
2025-11
Revenue YoY Growth
-0.26%
YoY Comparison
Gross Margin
+0.25%
Latest Quarter
Free Cash Flow
$-11907000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Given the negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio. The trailing PS ratio is 4.79, while the forward-looking metric, EV-to-Sales, is significantly higher at 65.79, reflecting the market's extreme growth expectations embedded in the current stock price. The massive gap between these sales-based multiples indicates the market is pricing in a dramatic future revenue acceleration, likely tied to the announced $37+ million in bookings. Peer comparison data is not available in the provided dataset, preventing a sector premium/discount analysis. Historically, the stock's own valuation has exploded; its current PS ratio of 4.79 is near the lower end of its recent historical range, which saw figures as high as 69.83 in Q2 FY2026 and 20.19 in Q4 FY2025. This apparent discount is misleading, as the recent astronomical PS ratios coincided with a much lower stock price and collapsing revenue; the current multiple reflects a market cap that has soared while sales have yet to catch up. The stock is thus being valued almost entirely on future potential, with historical context offering little anchor.
PE
-72.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -111x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-296.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company is burning cash at a rate of -$11.91M TTM free cash flow, with operating cash flow of -$1.39M last quarter, necessitating reliance on its $30.99M cash balance and external financing like the recent $9.20M stock issuance. Profitability has collapsed, with net margin deteriorating from -3.51% in Q3 FY2025 to -32.68% in the latest quarter, and gross margin contracting 815 basis points sequentially to 25.75%. Revenue has declined for three consecutive quarters, peaking at $18.31M and falling to $9.88M, indicating significant near-term execution risk before the booked orders convert.
Market & Competitive Risks center on valuation compression and narrative dependency. Trading at a forward EV/Sales of 65.79, the stock is priced for hyper-growth, leaving no room for error. A beta of 2.289 indicates it is 129% more volatile than the market, making it highly sensitive to sector rotations away from speculative tech or shifts in AI investment sentiment. Limited analyst coverage (only one firm providing estimates) contributes to inefficient price discovery and higher volatility, as the stock is driven more by retail speculation and news flow than grounded fundamental analysis.
Worst-Case Scenario involves a failure to convert bookings into timely, profitable revenue, coupled with a broader cooling of the AI investment theme. This could trigger a cascade of analyst downgrades, a loss of investor confidence, and a violent unwinding of the speculative premium. The stock could realistically revisit its 52-week low of $8.02, representing a downside of approximately -92% from the current price of $95.91. A more measured bear case, considering the new backlog, might see a pullback to the $30-$40 range (down -60% to -70%), which was the trading zone prior to the most recent explosive rally in April 2026.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to convert the $37.2M bookings backlog into timely, high-margin revenue, as evidenced by three consecutive quarters of declining sales. 2) Valuation & Financing Risk: The extreme valuation (EV/Sales 65.79) leaves no room for error, and continued cash burn (-$11.91M TTM FCF) may force dilutive equity financing. 3) Market & Volatility Risk: With a beta of 2.289, the stock is 129% more volatile than the market, making it highly susceptible to sector rotations and sentiment shifts away from speculative AI plays. 4) Customer Concentration Risk: The large backlog may be dependent on a small number of AI chipmakers, creating lumpy revenue and client dependency.
The 12-month forecast is highly uncertain, with three distinct scenarios. The Bull Case (25% probability) targets $150-$180, assuming flawless backlog conversion and margin recovery. The Base Case (50% probability), which is most likely, sees volatile consolidation in a $70-$100 range as growth materializes but valuation compresses. The Bear Case (25% probability) targets $30-$50 if execution stumbles and the AI narrative cools. The key assumption behind the base forecast is that the company will show sequential revenue improvement but struggle to achieve the growth rate implied by its current valuation, leading to a period of price consolidation after the parabolic rally.
Based on current financials, AEHR is dramatically overvalued. The company is unprofitable with declining revenue and negative cash flow, yet trades at a forward EV/Sales of 65.79. This multiple implies the market expects flawless execution and hyper-growth, pricing in revenue that is nearly 20x the latest quarterly run-rate. There is no historical or peer comparison that justifies this multiple on present fundamentals. The stock is fairly valued or potentially undervalued only if one fully believes in the imminent realization of the $196M annual revenue forecast and a return to strong profitability.
AEHR is a speculative buy only for investors with a very high risk tolerance and a short-to-medium term investment horizon. The potential upside is significant if the company executes on its $37.2M backlog and approaches the analyst's $196M revenue target, but this is already largely reflected in its extreme forward EV/Sales multiple of 65.79. The downside risk is severe, with a realistic bear-case target in the $30-$50 range (-60% to -70%) if execution falters. It is not a good buy for conservative investors, income seekers, or those unable to monitor its quarterly results closely.
AEHR is primarily suitable for short-to-medium term tactical investing, not long-term buy-and-hold. The company is in a critical proving phase over the next 2-4 quarters; its long-term viability depends on successfully navigating this inflection point. The extreme volatility (beta 2.289), lack of dividends, and current lack of earnings visibility make it a poor fit for a stable long-term portfolio. Investors should have a horizon of 6-18 months to assess whether the growth story is materializing, with a readiness to exit if the fundamental data turns negative. It is more akin to a venture capital-style bet than a traditional equity investment.